Geneva, Aug 26 (IANS) The number of newly reported monkeypox cases has decreased worldwide, according to the World Health Organization (WHO).
In the week from August 15-21, there were 21 per cent fewer cases than in the previous week, dpa news agency quoted the global health body as saying in a statement issued on Thursday.
In the previous four weeks, the numbers had been rising.
"This decrease may reflect early signs of a declining case count in the European region, which would need to be subsequently confirmed," said the statement.
The European Region includes 53 countries from the EU to Turkey, Turkmenistan, Russia and Israel.
In the North and South America region, however, the numbers continued to rise.
Worldwide, 5,907 cases were reported during the week, compared to 7,477 the week before.
In total, some 41,600 infections and 12 deaths have been reported to the WHO from 96 countries since the beginning of the year.
Presently, the US has the highest number of cases at 15,877.
Macy's similarly remade its traditional July Fourth fireworks show this year, swapping the big one-night spectacle for a series of smaller fireworks displays.
For Trump, it’s seen as a potential lifeline to Black and Hispanic voters, who are more likely to support vouchers and other school choice options, polls have found.
Fesler and O'Shaughnessy say adversaries like Russia and China are increasingly well-positioned to exploit the "seams" that currently exist between North America's air, sea and missile defence systems and early warning networks.
Biden plans stiff tax penalties for companies that manufacture U.S.-bound products outside the country and a crackdown on those that use offshoring to avoid paying taxes at home.
If elected, Biden said, he would impose stiff new tax penalties on companies that manufacture U.S.-bound products outside the country, create incentives for keeping jobs on U.S. soil and close what he called "Trump loopholes" that allow companies engaged in offshoring to avoid paying U.S. taxes.
A spokesperson for AstraZeneca, via a statement said that the company’s “standard review process triggered a pause to vaccination to allow review of safety data.”
.jpg "AstraZeneca vaccine trial not going ahead due to adverse reaction in a subject")